Somatic variants in epigenetic modifiers can predict failure of response to imatinib but not to second-generation tyrosine kinase inhibitors.
Nteliopoulos G, Bazeos A, Claudiani S, Gerrard G, Curry E, Szydlo R, Alikian M, Foong HE, Nikolakopoulou Z, Loaiza S, Khorashad JS, Milojkovic D, Perrotti D, Gale RP, Foroni L, Apperley JF.
Nteliopoulos G, et al. Among authors: nikolakopoulou z.
Haematologica. 2019 Dec;104(12):2400-2409. doi: 10.3324/haematol.2018.200220. Epub 2019 May 9.
Haematologica. 2019.
PMID: 31073075
Free PMC article.